EverQuote (EVER) Competitors $18.85 +0.06 (+0.32%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends EVER vs. HCAT, HSTM, TRUE, EB, MODN, RPD, SOUN, MGNI, RUM, and AVDXShould you be buying EverQuote stock or one of its competitors? The main competitors of EverQuote include Health Catalyst (HCAT), HealthStream (HSTM), TrueCar (TRUE), Eventbrite (EB), Model N (MODN), Rapid7 (RPD), SoundHound AI (SOUN), Magnite (MGNI), Rumble (RUM), and AvidXchange (AVDX). EverQuote vs. Health Catalyst HealthStream TrueCar Eventbrite Model N Rapid7 SoundHound AI Magnite Rumble AvidXchange EverQuote (NASDAQ:EVER) and Health Catalyst (NASDAQ:HCAT) are both small-cap finance companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and community ranking. Do analysts prefer EVER or HCAT? EverQuote presently has a consensus target price of $28.50, indicating a potential upside of 51.19%. Health Catalyst has a consensus target price of $11.71, indicating a potential upside of 59.08%. Given Health Catalyst's higher probable upside, analysts plainly believe Health Catalyst is more favorable than EverQuote.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score EverQuote 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Health Catalyst 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.75 Do institutionals and insiders believe in EVER or HCAT? 91.5% of EverQuote shares are owned by institutional investors. Comparatively, 85.0% of Health Catalyst shares are owned by institutional investors. 29.8% of EverQuote shares are owned by insiders. Comparatively, 2.5% of Health Catalyst shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has preferable valuation and earnings, EVER or HCAT? EverQuote has higher revenue and earnings than Health Catalyst. Health Catalyst is trading at a lower price-to-earnings ratio than EverQuote, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEverQuote$408.44M1.63-$51.29M$0.3455.44Health Catalyst$295.94M1.51-$118.15M-$1.35-5.45 Which has more volatility and risk, EVER or HCAT? EverQuote has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, Health Catalyst has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Does the media favor EVER or HCAT? In the previous week, EverQuote had 4 more articles in the media than Health Catalyst. MarketBeat recorded 12 mentions for EverQuote and 8 mentions for Health Catalyst. EverQuote's average media sentiment score of 1.18 beat Health Catalyst's score of 0.96 indicating that EverQuote is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment EverQuote 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Health Catalyst 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer EVER or HCAT? Health Catalyst received 109 more outperform votes than EverQuote when rated by MarketBeat users. However, 71.64% of users gave EverQuote an outperform vote while only 68.26% of users gave Health Catalyst an outperform vote. CompanyUnderperformOutperformEverQuoteOutperform Votes4871.64% Underperform Votes1928.36% Health CatalystOutperform Votes15768.26% Underperform Votes7331.74% Is EVER or HCAT more profitable? EverQuote has a net margin of 3.31% compared to Health Catalyst's net margin of -26.20%. EverQuote's return on equity of 13.94% beat Health Catalyst's return on equity.Company Net Margins Return on Equity Return on Assets EverQuote3.31% 13.94% 9.24% Health Catalyst -26.20%-7.51%-3.72% SummaryEverQuote beats Health Catalyst on 14 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get EverQuote News Delivered to You Automatically Sign up to receive the latest news and ratings for EVER and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVER vs. The Competition Export to ExcelMetricEverQuoteComputer & Data IndustryFinance SectorNASDAQ ExchangeMarket Cap$666.37M$78.86B$10.56B$8.82BDividend YieldN/A0.55%10.16%4.07%P/E Ratio55.4450.3649.3017.81Price / Sales1.63201.423,460.6574.38Price / CashN/A30.6730.5032.53Price / Book7.955.522.764.68Net Income-$51.29M$2.40B$995.76M$226.08M7 Day Performance-2.89%-1.99%-0.34%-2.04%1 Month Performance-2.03%2.61%1.82%0.06%1 Year Performance120.73%56.65%23.83%24.60% EverQuote Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVEREverQuote4.6793 of 5 stars$18.85+0.3%$28.50+51.2%+120.7%$664.25M$287.92M55.44610Analyst RevisionPositive NewsHCATHealth Catalyst4.6678 of 5 stars$7.36-2.4%$11.71+59.1%-5.0%$458.79M$295.94M0.001,300HSTMHealthStream4.0314 of 5 stars$31.30-2.9%$31.50+0.6%+22.8%$980.58M$279.06M48.151,092TRUETrueCar1.9166 of 5 stars$3.92-1.5%$4.56+16.4%+45.2%$346.09M$158.71M-13.52440EBEventbrite4.5436 of 5 stars$3.47-1.7%$6.58+90.0%-50.6%$341.99M$326.13M0.00880MODNModel N0.6239 of 5 stars$30.00flat$29.17-2.8%N/A$1.18B$249.46M-3,000,000.001,089Analyst ForecastRPDRapid71.7534 of 5 stars$41.06+5.2%$44.59+8.6%-21.6%$2.47B$777.71M65.182,228Analyst DowngradeSOUNSoundHound AI2.3713 of 5 stars$6.44-1.1%$7.64+18.7%+190.1%$2.34B$45.87M0.00200Gap UpMGNIMagnite2.3957 of 5 stars$16.03-1.4%$16.96+5.8%+101.6%$2.29B$619.71M267.17911Insider TradeRUMRumble1.848 of 5 stars$6.03+6.2%$8.00+32.7%+18.2%$2.21B$80.96M-9.5770Gap UpAVDXAvidXchange3.559 of 5 stars$10.71+0.7%$11.39+6.4%+8.4%$2.19B$380.72M532.001,600Analyst Forecast Related Companies and Tools Related Companies HCAT Competitors HSTM Competitors TRUE Competitors EB Competitors MODN Competitors RPD Competitors SOUN Competitors MGNI Competitors RUM Competitors AVDX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EVER) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EverQuote, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share EverQuote With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
